Marine biomedical industry refers to the production of marine biochemical drugs, health care products and genetic engineering drugs, such as genes, fermentation engineering drugs, genetic engineering vaccines, antibiotics, vitamins and blood products. Take marine life as raw material or extract effective components. The research and industrialization of marine drugs and marine biological products has now become a hot field for maritime powers to compete for.
However, compared with the United States, France and other developed countries, there are many pain points in the development of China's marine biomedical industry. For example, because the research and development of marine drugs takes longer and costs more, the research and development of marine drugs is more risky for pharmaceutical companies than other drugs. The international drug research and development cycle is generally 10- 15, but the research and development cycle of marine drugs currently on the market is generally more than 20 years, which means that marine biomedical development enterprises need to bear higher risks. In addition, the level of science and technology, capital investment, industrialization bottlenecks and other issues restrict the development of China's marine biomedical industry.
In addition, although the technical level of China's marine biomedicine is developing continuously, the technical level of China's marine biomedicine industry is still far behind that of the United States and France. Judging from the number of marine biomedical patent applications and public applications in China in recent years, the overall number of applications is not high, with only 17 in 20 19 years. Generally speaking, the development of marine biomedical technology in China is still in its infancy, and the technical activity is still relatively low. It can be seen that China's marine biomedical industry has a long way to go in the future, especially in marine biomedical technology.
Policy-driven, provinces increase industry investment.
In order to promote the development of China's marine biomedical industry, China has successively issued a number of encouragement and support policies. For example, from 2065438 to May 2007, the Thirteenth Five-Year Plan for the Development of National Marine Economy mentioned that it would focus on supporting innovative marine drugs with independent intellectual property rights and broad market prospects, and developing modern marine Chinese medicine products with national characteristics. 2065438+June 2009, Qingdao supported the development plan of "Blue Pharmacy" and set up the "China Blue Pharmacy Development Fund" with 5 billion yuan. In April 2020, the Guiding Opinions on Promoting the High-quality Development of Trade pointed out that breakthroughs should be made in key areas such as high-end equipment manufacturing, information technology and biomedicine.
With the support of these policies and driven by market demand, innovative marine drugs with independent intellectual property rights, health, safety, green and high efficiency will usher in good development opportunities. With the rise of the blue economic boom, coastal provinces such as Shandong, Guangdong, Zhejiang, Jiangsu and Fujian have increased their investment in the marine biomedical industry. Shandong has set up a development fund of "China Blue Drug Store" of 5 billion yuan to build six product research and development platforms, including modern marine drugs and modern marine Chinese medicine. Keep up with the development trend of international biotechnology, and adopt high-tech and modern synthetic technologies such as genetic engineering, cell engineering, enzyme engineering, biochemical engineering and biomedicine to carry out research and development of marine biomedicine. Relying on scientific research institutions such as Sun Yat-sen University and Nanhai Institute of Oceanography of Chinese Academy of Sciences, Guangdong has built a number of highly competitive and high value-added scientific and technological research and development platforms.
With the growth of market scale, there is great room for future growth.
With the support of the national "blue economy" strategy and the continuous improvement of marine biological extraction technology, China's marine biomedical industry has been developing continuously, which is the fastest growing field of marine industry in the past decade. According to the data of the State Oceanic Administration, in 20 19, the added value of China's marine biomedical industry reached 44.3 billion yuan, up 8.0% year-on-year, and there is huge room for future growth.
Note: According to the statistics of the State Oceanic Administration, the added value of the marine biomedical industry is calculated at the current price, which is different from the local statistics and the total data is not equal.
The research and development of marine biopharmaceuticals is characterized by large investment, high risk and long cycle. The government's support is of great significance to the development of China's marine biopharmaceuticals industry. With the development of marine economy, the continuous improvement of biotechnology and the support of government policies, the marine drug market in China will develop rapidly in the future.
The above data comes from the Analysis Report on Market Foresight and Investment Strategic Planning of China Marine Biomedical Industry by Forward-looking Industry Research Institute.